RESEARCH

Inadequate reporting quality of registered genome editing trials: an observational study

Diana Jurić1*, Michael Zlatin2 and Ana Marušić3

Abstract

Background: To assess registration completeness and safety data of trials on human genome editing (HGE) reported in primary registries and published in journals, as HGE has safety and ethical problems, including the risk of undesirable and unpredictable outcomes. Registration transparency has not been evaluated for clinical trials using these novel and revolutionary techniques in human participants.

Methods: Observational study of trials involving engineered site-specific nucleases and long-term follow-up observations, identified from the WHO ICTRP HGE Registry in November 2020 and two comprehensive reviews published in the same year. Registration and adverse events (AEs) information were collected from public registries and matching publications. Published data were extracted in May 2021.

Results: Among 81 eligible trials, most were recruiting (51.9%) phase 1 trials (45.7%). Five trials were withdrawn. Most trials investigated CAR T cells therapies (45.7%) and used CRISPR/Cas9 (35.8%) ex vivo (88.9%). Among 12 trials with protocols both registered and published, eligibility criteria, sample size, and secondary outcome measures were consistently reported for less than a half. Three trials posted results in ClinicalTrials.gov, and one reported serious AEs.

Conclusions: Incomplete registration and published data give emphasis to the need to increase the transparency of HGE trials. Further improvements in registration requirements, including phase 1 trials, and a more controlled publication procedure, are needed to augment the implementation of this promising technology.

Keywords: Clinical trials on genome editing as topic, Genome editing, Databases, Reporting

Background

Human gene therapy (GT) products are biological products that have a potential to fulfill unmet medical needs [1] but are also challenging to regulators because of highly complex information on their development and manufacture [1–4]. According to the FDA consideration, "human gene therapy products" are defined as “all products that mediate their effects by transcription or translation of transferred genetic material, or by specifically altering host (human) genetic sequences” [3]. The development of innovative approaches, including programmable nucleases [5–7], led to the explosion of interest for use of genome editing [8], and a move beyond the basic laboratory research to early clinical uses [5, 8–13]. The term “genome editing” refers “to the processes by which the genome sequence is changed by adding, replacing, or removing DNA base pairs” [3, 8].

Despite their potential for different diseases [14, 15], there are still emerging issues surrounding the safety and effectiveness of GT, including early failures [1], outcomes such as death [16], late-onset T-cell leukemia [17], and brain and spinal cord tumors [18]. Due to possible non-specific off-target genome changes, insertional mutagenesis with integrating vectors, or immune response to product components, participants in trials with genome editing-based GT products may experience unpredictable and delayed adverse events.

*Correspondence: diana.juric@mefst.hr
1 Department of Pharmacology, School of Medicine, University of Split, Soltanska 2, 21000 Split, Croatia
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
(AEs) [8, 19]. To better interpret that risk, monitoring of long-term safety is recommended [19, 20]. Although AEs are mandated to be reported for all interventional trials except phase 1 involving FDA-regulated drug, biological, or device products [21, 22], reporting transparency is still low [23–25].

The aim of our study was to assess the registration completeness and published data in journal articles for trials testing genome editing therapies.

Methods
Sample and inclusion criteria
On November 12, 2020, we retrieved clinical trials using genome editing technologies from the Human Genome Editing (HGE) Registry provided by the WHO International Clinical Trials Registry Platform (ICTRP) [26], without any set limitations. We also checked two comprehensive tables published in 2020 [5, 9] on trials that involved genome editing. A clinical trial was considered a “HGE trial” if it: 1) had a registry identification number and available registration protocol, 2) was registered on or before November 12, 2020, and 3) involved in vivo or ex vivo interventions using engineered site-specific nucleases to alter human cells for purposes of treating or preventing disease, or was 4) long-term follow-up (LTFU) observation with extended assessments. Basic laboratory studies on human cells or tissues focusing on cellular, molecular, biochemical, genetic, or immunological mechanisms, and duplicate trials registered in two or more registries, were excluded from the analysis.

Publication search
Corresponding publications were identified in May 2021 by screening the following sources: 1) the Publications subheading under the ClinicalTrials.gov Descriptive Information heading, 2) PubMed/MEDLINE, and 3) Scopus. The manual search used 1) trial unique identification number, and 2) combination of search terms for each trial: intervention name, nuclease platform used, edited gene/cells, condition, study phase, and all names under “investigators” field in different public registries.

WHO ICTRP data extraction
We extracted data on 21 out of 24 items from the WHO Trial Registration Data Set (TRDS) [27] until February 2021. Administrative items (3, 7 and 8) were not extracted. We also extracted data describing HGE technology (edited cells, target gene, nuclease platform used, and modes of delivery).

For trials with posted results, we calculated the median time for results reporting from the primary completion date (PCD) [22]. In May 2021, we re-evaluated whether trials posted results in the registry.

Data analysis
Registration and publication data were extracted independently by two reviewers (M.Z., D.J.), after all three investigators (M.Z., D.J., A.M.) established the final extraction protocol through the pilot extraction of a 10% random sample. The data are presented as frequencies and medians with 95% confidence intervals. MedCalc version 20.008 (MedCalc Software, Ostend, Belgium) was used.

Results
General characteristics of registered HGE trials
From 122 identified trials (Fig. 1), we excluded 41 (33.6%) because of in vitro trial design, incorrect identification, clustered regularly interspaced short palindromic repeats (CRISPR)-based diagnosis as trial purpose, and registration of the same trial in two registries. Of the remaining 81 trials, most were interventional (96.3%), with single group assignment as the most common model (60.3%, Table 1). The majority of trials with administered interventions were without blinding (78.2%), a half were in phase 1 (47.4%), and 25 interventional trials (32.1%) reported the use of a FDA-regulated drug product under their study intervention. The use of the randomization method was reported in 6 ClinicalTrials.gov trials that had parallel design, but detailed information regarding the randomization process, mostly challenging to these trials, were missing.

In 3 trials that clearly noted the use of a sham control, patient’s lymphocytes were collected and infused back to the patients without any genetic or engineered modification ex vivo.

Three trials were registered as LTFU trials, referring to subjects treated with CCR5-zinc-finger nuclease (ZFN) modified autologous T cells, CRISPR/Cas9-associated protein (Cas) 9 modified autologous hematopoietic stem cells, and UCART19, respectively.

Most trials included participants of both genders (91.4%, Supplementary Table 1), aged 18–70. Among 7 trials that investigated HGE technology in a single gender, 1 explicitly provided a “gender eligibility description” (NCT03525652).

Among 52 trials that had any registration entry for individual participant data (IPD) sharing statement, 22 trials (42.3%) will not share de-identified IPD. Regarding the data monitoring committee, 28 trials (34.6%) stated “no”; 43 (53.1%) stated “yes”, and 10 (12.3%) did not provide any information.

More than half of the trials had a “recruiting” status (51.9%) and were prospectively registered (67.9%, Supplementary Table 2). For almost a third of trials, the information on investigators were absent (30.9%). Most
HGE trials were sponsored by industry (44.4%) and conducted in China (48.1%). Among 33 trials whose study completion date (SCD) was until May 2021 (median 2019, 95% CI 2018–2020, range 2013–2021), 3 trials (9.1%) had a “not yet recruiting” status, whilst 7 (21.2%) were still recruiting.

In 2017 or 2018, 4 trials changed their status to “unknown” from “not yet recruiting”, “recruiting”, or “active, not recruiting”, without any explanation. Among 5 trials that were withdrawn, 3 listed “no funding” as an explanation, 1 listed “sponsor’s decision and not a consequence of any safety concern”, and 1, led by Chinese scientist He Jiankui (ChiCTR1800019378), stated that “the original applicants cannot provide the IPD for reviewing.”

Only 3 trials from ClinicalTrials.gov submitted and posted their results until May 2021 (Supplementary Table 2); results reporting times were 45.5, 31.8 and 28.0 months, respectively. All 3 trials, testing editing of CCR5 or PDCD1 gene in T cells, reported no deaths within 1 or 2 years. A single trial (NCT01543152) reported serious AEs (SAEs): staphylococcal cellulitis and substance abuse.
Table 1  Design of 81 trials on genome editing in humans registered in WHO ICTRP

| Trial design features | No. (%) of trials |
|-----------------------|-------------------|
| **Study type:**       |                   |
| Interventional\(^a\) | 78 (96.3)         |
| Long-term follow-up\(^b\) | 3 (3.7)   |
| **Primary purpose:** |                   |
| Treatment\(^c\)      | 63 (80.8)         |
| Other                | 2 (2.6)           |
| Not provided\(^d\)   | 13 (16.7)         |
| **Study phase:**     |                   |
| Phase 0              | 3 (3.8)           |
| Early phase 1        | 4 (5.1)           |
| Phase 1              | 37 (47.4)         |
| Phase 2              | 7 (9.0)           |
| Phase 1/2            | 20 (25.6)         |
| Stated “not applicable” | 6 (7.7)   |
| Not provided         | 1 (1.3)           |
| **Allocation:**      |                   |
| Randomized controlled trial\(^e\) | 6 (7.7) |
| Non-randomized trial | 23 (29.5)         |
| Not precisely stated, but single arm reported | 7 (9.0) |
| Stated “not applicable” | 38 (48.7) |
| Not provided         | 4 (5.1)           |
| **Intervention study model:** |       |
| Single group         | 47 (60.3)         |
| Parallel             | 14 (17.9)         |
| Sequential           | 15 (19.2)         |
| Not provided         | 2 (2.6)           |
| **Masking:**         |                   |
| Open-label           | 61 (78.2)         |
| Single-blind\(^f\)  | 3 (3.8)           |
| Double-blind\(^g\)  | 1 (1.3)           |
| Stated “not applicable” | 5 (6.4)   |
| Not provided         | 8 (10.3)          |
| **Placebo:**         |                   |
| Placebo comparator noted\(^h\) | 3 (3.8) |
| Not provided         | 75 (96.2)         |

Abbreviation: WHO ICTRP World Health Organization International Clinical Trial Registry Platform

\(^a\) Among 78 trials, 11 (14.1\%) were incorrectly classified as observational in their registration protocol (1 trial from CT.gov, NCT02867345, and 10 trials from ChiCTR), and 1 (1.3\%) ChiCTR trial had “Cause/Relative factors study” stated under its study type (ChiCTR1800019378)

\(^b\) NCT04208529 was registered as an observational study to evaluate the long-term safety and efficacy in subjects who received CTX001 in 2 trials (NCT03655678 and NCT03745287) analyzed in this study as interventional trials, whilst other 2 LTFU trials, NCT04201782 and NCT02735083, had an interventional study type in their registration protocol and did not specify to which trials they referred to

\(^c\) Characteristics related only to trials with an administered intervention (n = 78)

\(^d\) One trial had “therapy” among registered terms under the trial scopes in EudraCT

\(^e\) Among these 13 trials, 12 were registered in the Chinese trial registry, without the specific field for primary purpose, and 1 trial had an inappropriately registered observational type in CT.gov (NCT02867345)

\(^f\) CT.gov trial mentioned previously (NCT02867345). This trial is among trials without provided data for all parameters in the table signed with the superscript “c”

\(^g\) One parallel ClinicalTrials.gov trial reported “randomized” under the Study Design field used for data analysis, but under the Detailed Description field also reported “non-randomized” (NCT03299828)

\(^h\) Three trials from ClinicalTrials.gov (NCT03525652, NCT03525782, and NCT03706326)

\(^i\) One ClinicalTrials.gov trial (NCT03666871)

\(^j\) Two trials were open-label (NCT02863913 and NCT02867332), and one was single-blind (NCT03525782)
The median follow-up time for 21 trials without any results entry in ClinicalTrials.gov and SCD until May 2021 was 17.3 months from the SCD (95% CI 6.2–32.6, range 2.2–100.0 months).

Characteristics of HGE technologies
The trials mostly tested the intervention in a single health condition (median 1, 95% CI 1.0–1.0, range 1–14), mostly cancers (70.4%) and HIV infection (14.8%) (Table 2).

Only 9 (11.1%) trials applied HGE tools directly to a participant’s organism, using nucleases for the treatment of HPV-related malignant neoplasm, hemophilia B, mucopolysaccharidosis, or different eye disorders.

We identified a trial on germline editing (ChiCTR1800019378) involving married Chinese couples with HIV seropositivity and fertility problems. The trial resulted in the birth of twin girls with CRISPR disabled CCR5 gene [28].

CRISPR/Cas9 was the most utilized genome editing platform (35.8%), followed by ZFN (21.0%, Table 2). Out of 33 trials that lacked registration data on the nuclease platform used, 21 (63.6%) were conducted in China.

The description of the delivery platform was absent for the majority of trials (80.2%). Half of trials that provided this information used adeno-associated virus vectors or mRNA (9.9%).

The development of chimeric antigen receptor (CAR) T cells was in the focus of 37 trials (45.7%); 27 of them (73.0%) studied allogeneic CAR T cells, 8 (21.6%) autologous, whilst for 2 trials (5.4%) CAR T cells origin was not precisely stated. B-lymphocyte antigen CD19 was the most commonly targeted protein among CAR therapies (n = 18, 48.6%, Table 3). Considering all included trials, knock-out of an immune checkpoint PD-1 was the sole aim for almost a fifth of trials (18.5%, Table 3).

Only 13 (16.0%) out of 81 trials explicitly stated the number of the ethics committee document or date of approval.

Comparison of registered and published data
Out of 81 trials, 12 trials (14.8%) in ClinicalTrials.gov had results published in a journal (9 full-text and 3 progress reports).

---

**Table 2** Characteristics of genome editing methodologies used in 81 trials registered in WHO ICTRP

| Genome editing characteristics | No. (%) of trials |
|-------------------------------|-------------------|
| **Platform:**                |                   |
| ZFN                          | 17 (21.0)         |
| TALEN                        | 1 (1.2)           |
| CRISPR/Cas9                  | 29 (35.8)         |
| TALEN and CRISPR/Cas9        | 1 (1.2)           |
| Not stated                   | 33 (40.7)         |
| **Testing method:**          |                   |
| In vivo                      | 9 (11.1)          |
| Ex vivo                      | 72 (88.9)         |
| **Disease applications:**    |                   |
| HIV infection and AIDS       | 12 (14.8)         |
| Neoplasms                    | 57 (70.4)         |
| Hematological disorders      | 8 (9.9)           |
| Metabolic diseases           | 2 (2.5)           |
| Eye diseases                 | 2 (2.5)           |
| **Edited cells:**            |                   |
| T cells                      | 24 (29.6)         |
| CAR T cells                  | 37 (45.7)         |
| Tumor infiltrating lymphocytes| 2 (2.5)           |
| Stem or progenitor cells      | 8 (9.9)           |
| Hepatocytes                  | 3 (3.7)           |
| Epithelial cells             | 3 (3.7)           |
| Human embryos                | 1 (1.2)           |
| Not stated                   | 3 (3.7)           |
| **Delivery:**                |                   |
| Adenovirus                   | 1 (1.2)           |
| AAV                          | 4 (4.9)           |
| Lentivirus                   | 2 (2.5)           |
| Lentiviral and electroporation| 3 (3.7)          |
| Plasmid                      | 1 (1.2)           |
| mRNA                         | 4 (4.9)           |
| Intratumoral injection       | 1 (1.2)           |
| Not stated                   | 65 (80.2)         |

**Abbreviations:** AAV Adeno-associated virus, CAR Chimeric antigen receptor, CRISPR Clustered regularly interspaced short palindromic repeats, TALEN Transcription activator-like effector nuclease, WHO ICTRP World Health Organization International Clinical Trial Registry Platform, ZFN Zinc finger nuclease

a Trial conducted in China, using TALEN in vivo (suppository) in the treatment of HPV-related cervical intraepithelial neoplasia (CIN) (NCT03226470)

b Trial conducted in China, using CRISPR/Cas9 and TALEN in vivo (plasmids in gel) in the treatment of HPV-associated CIN (NCT03057912)

c HPV-related malignant neoplasm was an investigated condition in 3 trials testing only ZFN, TALEN, or CRISPR/Cas9 (NCT02800369, NCT03226470, NCT03057912); hemophilia B or mucopolysaccharidosis in 4 trials using ZFN platform (NCT02695160, EUCTR2017-004805-42-GB, NCT03041324, NCT02702115); and different diseases of the visual system in the remaining 2 trials (and) – one used CRISPR/Cas9 (NCT04560790) and another did not specify the nuclease platform used (NCT03872479)

d Including beta-thalassemia, sickle cell disease, and hemophilia B

e Referring to mucopolysaccharidosis I and II

f “Blindness, Leber congenital amaurosis 10, vision disorders, hereditary eye diseases, congenital eye disorders, retinal disease/degeneration” noted in NCT03872479; “viral keratitis, blindness, Herpes simplex virus infection” recorded in NCT04560790

**Table 2** (continued)  
lymphocytes (CTLs), or only T cells

| No. (%) of trials |
|-------------------|
| b Including hematopoietic stem/progenitor cells (HSPCs), hematopoietic stem cells (HSCs), and induced hematopoietic stem cells (iHSCs)
| c CRISPR embryo editing by Chinese scientist He Jiankui, which later resulted in birth (ChiCTR1800019378) |
Table 3  Registered targets in 81 clinical trials on genome editing in human participants from WHO ICTRP

| WHO ICTRP targets          | No. (%) of trials |
|---------------------------|-------------------|
| **Single target**         |                   |
| BCL11A gene               | 5 (6.2)           |
| CCR5 gene                 | 10 (12.3)         |
| CEP290 gene               | 1 (1.2)           |
| CISH gene                 | 2 (2.5)           |
| Factor IX gene            | 2 (2.5)           |
| HBB gene                  | 1 (1.2)           |
| HPV oncogenes E6 or E7    | 3 (3.7)           |
| ID5 gene                  | 1 (1.2)           |
| IDUA gene                 | 1 (1.2)           |
| PDCD1 gene                | 15 (18.5)         |
| CAR T cells therapy targets: |             |
| BCMA                      | 3 (3.7)           |
| CD7                       | 2 (2.5)           |
| CD19                      | 12 (14.8)         |
| CD22                      | 1 (1.2)           |
| CD70                      | 2 (2.5)           |
| CD123                     | 2 (2.5)           |
| CS1                       | 1 (1.2)           |
| **Multiple targets**      |                   |
| PDCD1, NY-ESO-1, TRAC     | 1 (1.2)           |
| PDCD1, mesothelin (CARTs) | 2 (2.5)           |
| PDCD1, CD19 (CARTs)       | 2 (2.5)           |
| PDCD1, MUC1 (CARTs)       | 3 (3.7)           |
| CCR5, CD4 (CARTs)         | 1 (1.2)           |
| CD19 and CD20/CD22 (CARTs)| 1 (1.2)           |
| CD19 and HPK1 (CARTs)     | 1 (1.2)           |
| CD19, CD52, TRAC (CARTs)  | 1 (1.2)           |
| CD19, B2M, TRAC (CARTs)   | 1 (1.2)           |
| IL13 zetakine/HyTk (CARTs)| 1 (1.2)           |
| CD7 and CD28 (CARTs)      | 1 (1.2)           |
| **Not stated**            | 2 (2.5)           |

Abbreviations: BCL11A Mouse B cell lymphoma factor 11A, B2M Beta-2-microglobulin, CAR Chimeric antigen receptor, CARTs Chimeric antigen receptor T cells, CCR5 Chemokine receptor 5, CD Cluster of differentiation, CEP290 Centrosomal protein 290, CISH Cytokine-induced SH2 protein, HBB Hemoglobin subunit beta, HPK1 Hematopoietic progenitor kinase 1, HPV Human papillomavirus, IDUA α-L-iduronidase, MUC1 Mucin 1, cell surface associated, NY-ESO-1 New York esophageal squamous cell carcinoma 1, PDCD1 Programmed cell death 1, TRAC T cell receptor alpha chain, WHO ICTRP World Health Organization International Clinical Trial Registry Platform

For half of the trials, inclusion criteria were less informative in the publication than in the registry or were not specifically reported (Table 4). A sample size smaller than registered was reported in 5 out of 9 full-text reports. Participant’s age and sex matched in both sources for just over half of the trials.

The trials registered a median of 1 primary outcome measures (POMs) (95% CI 1–2, range 1–7) and 5.5 secondary (SOMs) (95% CI 2.0–10.6, range 1–21) in ClinicalTrials.gov. AEs were included in the registered POMs for all trials, except one (NCT03164135), which did not include AEs under any outcome measure. The number and description of SOMs matched in published full-text and ClinicalTrials.gov for 2 out of 12 trials (Table 4).

A single trial, declared as a first-in-human phase 1 trial testing CRISPR/Cas9 PD-1-edited T cells in patients with advanced NSCLC (NCT02793856), had results both published and posted in ClinicalTrials.gov. The time frame of AE data collection matched in both sources. The total number of participants with grade 1/2 treatment-related AEs were congruently reported, but SAEs during follow-up were not reported in ClinicalTrials.gov. No death was reported in the registry data element “All-cause mortality”, but the article noted that 11 out of 12 participants died from tumor progression within 2 years.

Discussion

Our study showed that registered trials using in vivo or ex vivo genome editing technology were mostly prospectively registered and recruiting phase 1 trials, focused mostly on immunotherapy that uses specially altered T cells, CAR T cell therapy, for different types of cancer. Trial results were underreported both in the registries and journal publications. All trials were related to somatic interventions, except a single one that resulted in a birth of two children. This trial involved major ethical violations and a call for international moratorium on the clinical use of human germline editing [29, 30].

In interpreting the findings, the following limitations should be addressed. The HGE Registry is a global registry recently created to track research on human genome editing [26] in the WHO ICTRP, which assembles the trial registration data sets provided by primary registries [31, 32]. However, taking into account that we identified additional 13 trials from two recently published overviews of trials on genome editing, there is a possibility that advanced search tools available at this moment in ICTRP are not sensitive and specific to identify all HGE trials. The number of trials we identified by combining the search of registries and published overviews is the highest among studies published to 2021 [5, 9, 11, 12]. As the trials on HGE were mostly in early phase 1 or phase 1 (51%), which are not subject to recently updated FDAAA registration and results reporting requirements [33], the sample may not be fully representative. We collected trial characteristics by assessing registration protocols that were not always complete.

The finding that only 14% of trials were completed could serve as another explanation for the poor results
Table 4  Comparison of selected protocol information registered and published for 12 ClinicalTrials.gov trials on genome editing

| Protocol in registry vs. publicationsa | No. (%) of trials |
|--------------------------------------|--------------------|
| Sample size                          |                    |
| Equal absolute number in both sources| 4 (33.3)           |
| Smaller sample size in publication   | 8 (66.7)           |
| Published full-textb                 | 5 (41.7)           |
| Published abstract                   | 3 (25.0)           |
| Eligibility age                      |                    |
| Congruent in both sourcesc           | 7 (58.3)           |
| Reported different inclusion age range| 5 (41.7)           |
| Published full-text                  | 4 (33.3)           |
| Published abstract                   | 1 (8.3)            |
| Eligibility sex                      |                    |
| Congruent in both sourcesd           | 8 (66.7)           |
| Sex not reported in publication      | 4 (33.3)           |
| Published full-text                  | 2 (16.7)           |
| Published abstract                   | 2 (16.7)           |
| Other inclusion criteria             |                    |
| Congruent in both sourcesf           | 3 (25.0)           |
| More informative in registryg        | 3 (25.0)           |
| More informative in article, with changed particular criteriah| 1 (8.3) |
| Only diagnosis defined with different levels of details| 2 (16.7) |
| Inclusion criteria not specifically stated in publicationi| 3 (25.0) |
| Exclusion criteria                   |                    |
| Congruent in both sourcesd           | 1 (8.3)            |
| More informative in registryg        | 4 (33.3)           |
| More informative in publication      | 1 (8.3)            |
| Exclusion criteria not specifically stated in publicationi| 6 (50.0) |
| Primary outcome measures (POMs)      |                    |
| Congruent in both sourcesd           | 9 (75.0)           |
| New outcome introduced in publicationk| 1 (8.3)           |
| POMs not reported clearly and separately from SOMs in article, but all registered POMs congruent to published| 2 (16.7) |
| Secondary outcome measures (SOMs)    |                    |
| Congruent in both sourcesd           | 2 (16.7)           |
| More informative in registryg        | 1 (8.3)            |
| New outcomes introduced in article   | 2 (16.7)           |
| Particular outcomes missing in progress report abstract| 2 (16.7) |
| One registered SOM published as POM  | 1 (8.3)            |
| POMs not reported clearly and separately from SOMs in article, but particular registered SOMs omitted in publication| 2 (16.7) |
| SOMs not registered in ClinicalTrials.gova| 2 (16.7) |

---

* A total of 12 trials was published: 9 as a full-text and 3 as an abstract of the progress report

* NCT03164135: registered vs. published 5 vs. 1; NCT02808442: 13 vs. 7; NCT03655678 and NCT03745287: 45 vs. 1 (reported preliminary results; the first patient included); NCT02746952: 25 vs. 14

* Two trials were published in a form of an abstract

* NCT03525782: registered 18–70 years, published 36–84; NCT02808442: registered up to 17 years, published 6 months-18 years; NCT03655678 and NCT03745287: registered 12–35, published 18–35; NCT02746952: registered 16–49, published 16–70

* One trial was published in a form of an abstract

* One abstract was included, with a statement: “Patients were recruited according to the criteria in NCT03525782”

* Along with different levels of details, one trial also modified a particular inclusion criterion in the article (NCT02793856): stage IV non-small cell lung cancer and expected life span ≥ 6 months in the registry vs. stage IIIIB or IV NSCLC and a life expectancy of over 3 months in the publication

* One trial was published as an abstract (NCT02702115), and two other reported a clinical summary of each included patient in the article, including the time of the first diagnosis of target disease, used therapy, intervention protocol, and safety outcomes (NCT03164135 and NCT03399448)

* One trial had ‘prior anti-CD19 cell therapy’ as an exclusion criterion in ClinicalTrials.gov, whilst in the published abstract, this treatment was allowed (NCT03939026)

* Three trials were published in a form of an abstract

* Safety was registered POM, whilst in the article safety along with feasibility were noted (NCT02793856). Feasibility was defined “by sufficient and viable edited T cells being able to be manufactured from the majority of enrolled patients”
reporting rate identified in primary registries. It is important to point out that all trials whose status was noted as completed were from ClinicalTrials.gov, the registry with a structured database for results dissemination. Of these completed trials, phase 1 was reported for 64%. However, our findings are consistent with similar studies showing that reporting of results has not yet become routine in research practice [34, 35], especially for trials at earlier stages [36, 37]. Anderson et al. showed that only 13% of 13,327 analyzed trials reported summary results within 1 year after completion [37]. Still, it is difficult to interpret the rate of results reporting for trials involving technologies that are inapplicable to conventional drugs, and for which regulatory requirements are still not fully established. In line with that, regulatory reforms for phase 1 trials should be considered in order to optimize the benefits and lessen potential harms from trials including HGE. Among the only 3 completed trials with results registered until May 2021, we showed that none has reported deaths and only one reported SAEs. The AEs underreporting in GT trials was already an issue in 2000 after the first publicly identified death of trial participant [16], when NIH announced that only 39 out of 691 GT-related SAEs in the last 7 years had been reported promptly, as required [38]. Despite 14% trials having completed status, a total of 33 trials (41%) reported SCD before May 2021. Among them, 21 trials (64%) were from ClinicalTrials.gov and remained without submitted results within the median follow-up time of 1.4 years after the SCD. The number of withdrawn, terminated, or trials of unknown status, and identified discrepancies in recruitment status and SCD, all point to challenges in ensuring high quality of data in public registries in general, and for HGE trials in particular. This is in line with the common inadequate updating of registered data [39, 40] even after more than 15 years of the implementation of trial registration [32] and more than 13 years of the legal mandate for results registration [22]. However, the prospective registration rate of almost 70% among HGE trials is higher than the reported 42% prospective registration rate from a 2018 study of 10,500 RCTs published in 2105 journals [41]. Prospective protocol registration is especially important for HGE trials since an expert assessment of publicly available information might prevent unethical, unsafe, illegal, or research without proper scientific justification to be conducted [42].

The discrepancies between the registry and corresponding publications regarding protocol and safety data are another issue of concern. It should be noted that the publication rate of 15% correlates with the percentage of trials with completed status reported under the recruitment information registration field. In a single trial that had both registered and published results, we identified absent reporting of SAEs and all-cause mortality in ClinicalTrials.gov. Moreover, in comparison to registered data, eligibility criteria were mostly underreported in publications. Since incomplete reporting of trial data is often credited to space restrictions in journals [43], the peer-review process may play a more important role in augmenting trial transparency. Nonetheless, it is important to keep in mind that 58% trials had SCD after May 2021, and that a full-text article was identified for only 9 trials at the moment of publication search.

Almost half of the included trials investigated applications of CAR T cells in human subjects. The fast evolution of CAR T cell therapies in both number and type [44] guided the recent inclusion of an annex on CAR T cells in EMA's guidance on the development of new medicinal products for human use containing genetically modified cells [45]. Universal CAR T cells for specific antigens of interest were generated from allogeneic T cells from healthy donors in more than 70% of the previously mentioned trials. However, these “off-the-shelf” products for large-scale clinical applications are still at their infancy, waiting for the establishment of clinical, industrial, and regulatory standards [46].

Our study showed that CRISPR technology were used more often than ZFNs and TALENs, which could be partially attributed to the difficulty in cloning and protein engineering for ZNF and TALEN, and their less simple and flexible use [12, 47]. The CRISPR technique can be readily and affordably adapted to simultaneously target genome sequence at multiple sites, with remarkable efficiency [48]. Despite that, the potential immunogenicity to CRISPR-Cas9 proteins could be a potential limitation for the use in humans [49], and should be monitored in HGE trials.

It is difficult to discuss the vector systems used for HGE since 80% trials did not register this information. However, among trials with delivery platform recorded, viral vectors were among the most commonly used, probably because they lack the propensity to integrate or reactivate following latency and thus carry a lower risk of delayed AEs [19].

Regarding trial design, the majority of identified ICTRP trials were early-phase trials, initially evaluating safety, tolerability, or feasibility of administration of investigational products [1]. RCTs are generally recommended, according to the EMA's guidance related to clinical aspects of GT products from 2018, but with acceptable alternatives if appropriately justified [2]. Early-phase design for GT products is more complex than for other product types, as stated in FDA's guidance released in 2015, and a case-by-case estimation is recommended in the trial planning [1].
Keeping in mind that the use of blinding and the control group in phase 1 or 2 are generally not as crucial as for confirmatory efficacy trial [1], only 4 out of 78 identified interventional HGE trials were blinded. The placebo comparator group was used in 3 trials focused on cancer immunotherapy and included an invasive procedure for the collection of patient’s T lymphocytes. Despite the fact that such a control could help differentiate product-related from procedure-related effects and be relevant for phase 3 trial as well, the use of the invasive procedure in the control group may be an important risk [1].

The finding that more than 80% of trials registered in WHO ICTRP clearly reported non-inclusion of healthy subjects is in line with the recently mentioned FDA’s recommendations [1], regarding unacceptable benefit-risk ratio in most trials with GT products.

The minimal age of participants included in the trials was below 11 years for 15% trials, whilst 56% trials included patients 65 years of age and older. Since specific effects of HGE could be different in children, adults or the elderly, such as the immunogenicity of a viral vector, taking vulnerable populations into consideration during GT development is encouraged in both EMA’s [2] and FDA’s guidance [1].

It is important to point out that pre-market trials of reasonable duration and sample size cannot fully predict the durability of response and the risk for delayed AEs, which makes the clinical review of HGE products more challenging in comparison with conventional drugs [4]. In our study, 3 LTFU studies were identified, but only 1 specified the duration of the extension study, where enrolled subjects will be evaluated for a total of 12 years (NCT04201782). This is in line with recommended “up to fifteen years for genome editing products” in current FDA guidance on LTFU after administration of human GT products [19], and recently updated EMA guidance [45].

Only 20% of analyzed trials were willing to provide an access to IPD and enable the re-use of data. Public posting of informed consent form (ICF) in the trial registry is still not required by the 24-item WHO TRDS, but it might help safeguard subjects from unethical behavior that in the past HGE trials resulted in death or SAEs [50]. In this context, we propose to broaden current WHO registration data elements specifically for HGE trials by including ICF, as well as expanded access information, which should follow the appropriate FDA regulations (21 CFR 312) [51]. Despite the value of data collected during the compassionate use of conventional drugs is mostly considered as limited [52], non-trial pre-approval use might provide important information on outcomes and AEs related to this unique class of therapeutics, mostly intended for patient populations that may be small, and whose effects in most cases cannot be reversed [53]. Other steps required to improve the transparency of HGE trials are more demanding, since the WHO ICTRP platform gathers trial registration data sets provided by different primary registries, still not completely complying with the WHO TRDS [54]. However, in 2021 WHO launched recommendations on the governance of HGE on a global scale, including also their trial registration, for which the “traditional” international standards should be particularly adapted [42]. Special emphasis should be put on having the appropriate ethics approval before the inclusion in the WHO HGE Registry. Furthermore, a small expert committee should be established, whose role would be to regularly screen the Registry and assess the compliance of planned and ongoing HGE trials, using a unique registration data set, yet to be standardized [42]. Governments, relevant healthcare and scientific organizations, ethic committees, funders, researchers, journal editors, and reviewers, should put exceptional efforts to enable these potentially life-saving technologies to be responsibly integrated into clinical practice.

Conclusions

To support safe innovation in this field, product developers should be provided with more specific regulatory guidance reflecting accumulating clinical experience and referring explicitly to HGE products; their development, manufacture, product approval, and follow-up, as well as registration technical requirements. High quality, informative and timely registration of trial protocol and results should be a prerequisite in the clinical regulatory procedure, and the international HGE Registry provided by WHO is a critical and necessary first step toward increasing the transparency of trials on human genome editing, with many fields for advance.

Abbreviations
AE: Adverse event; CAR: Chimeric antigen receptor; Cas9: CRISPR-associated protein 9; CCR5: Chemokine receptor 5; CFR: The Code of Federal Regulations; CRISPR: Clustered regularly interspaced short palindromic repeats; EMA: European Medicines Agency; FDA: Food and Drug Administration; FDAAA: Food and Drug Administration Amendments Act; GT: Gene therapy; HGE: Human genome editing; ICF: Informed consent form; IPD: Individual participant data; LTFU: Long-term follow-up; NCT number: National Clinical Trial number; NIH: National Institutes of Health; NSCLC: Non-small cell lung cancer; PCD: Primary completion date; PD-1: Programmed cell death protein 1; PDCCD1: Programmed cell death protein 1; POM: Primary outcome measure; RCT: Randomized controlled trial; SAE: Serious adverse event; SCD: Study completion date; SOM: Secondary outcome measure; TALEN: Transcription activator-like effector nucleases; UCART19: Allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor; WHO ICTRP: World Health Organization International Clinical Trial Registry Platform; WHO TRDS: World Health Organization Trial Registration Data Set; ZFN: Zinc finger nuclease.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12874-022-01574-0.

Additional file 1: Supplementary Table 1. Characteristics of participants included in 81 trials using HGE technologies and registered in WHO ICTRP.

Supplementary Table 2. Characteristics of conduct of 81 trials using HGE technologies and registered in WHO ICTRP.

Acknowledgements

Not applicable.

Authors' contributions

All authors (DJ, MZ, AM) generated the idea, designed the study, and selected the trials. DJ and MZ extracted data after all authors consent to the selection of trials and final extraction protocol. All authors interpreted and analyzed the data. DJ and MZ drafted the article, while AM critically revised it for important intellectual content. All authors approved the submitted version. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding

This study was funded by the Croatian Science Foundation ("Professionalism in Health—Decision making in practice and research, ProDeM") under Grant agreement No. IP-2019-04-4882. The funder had no role in the design of the study, the collection, analysis, and interpretation of the data, and the decision to approve publication of the finished manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Supplementary Information

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author details

1 Department of Pharmacology, School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia. 2 School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia. 3 Department of Research in Biomedicine and Health, School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia.

Received: 21 September 2021 Accepted: 14 March 2022 Published online: 02 May 2022

References

1. US Food and Drug Administration. Considerations for the design of early-phase clinical trials of cellular and gene therapy products. 2015. https://www.fda.gov/media/106369/download. Accessed 30 June 2021.

2. European Medicines Agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. 2018. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-aspects-gene-therapy-medicinal-products_en.pdf. Accessed 30 June 2021.

3. US Food and Drug Administration. Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs). 2020. https://www.fda.gov/media/113760/download. Accessed 30 June 2021.

4. US Food and Drug Administration. FDA continues strong support of innovation in development of gene therapy products. 2020. https://www.fda.gov/news-events/press-announcements/fda-continues-strong-support-innovation-development-gene-therapy-products. Accessed 3 Mar 2021.

5. Ernst MPT, Broeders M, Herrero-Hernandez P, Oussoen E, van der Ploeg AT, Pijnappel W Ready for repair? Gene editing enters the clinic for the treatment of human disease. Mol Ther Methods Clin Dev. 2020;18:532–57. https://doi.org/10.1016/j.thermtd.2020.06.022.

6. Broeders M, Herrero-Hernandez P, Ernst MPT, van der Ploeg AT, Pijnappel W. Sharpening the molecular scissors: advances in gene-editing technology. iScience. 2020;23(1):100789. https://doi.org/10.1016/j.isci.2019.100789.

7. Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):397–405. https://doi.org/10.1016/j.tibtech.2013.04.004.

8. National Academies of Sciences, Engineering, and Medicine. 2017. Human Genome Editing: Science, Ethics, and Governance. The National Academies Press. Washington, DC. https://doi.org/10.17226/24623.

9. Li H, Yang Y, Hong W, Huang M, Wu M, Zhou X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5(1):1. https://doi.org/10.1038/s41392-019-0089-y.

10. Carroll D. Genome editing: past, present, and future. Yale J Biol Med. 2017;90(4):653–9.

11. Cornu TI, Mussolin C, Cathomen T. Refining strategies to translate genome editing to the clinic. Nat Med. 2017;23(4):415–23. https://doi. org/10.1038/nm.4313.

12. Ghosh D, Venkataramani P, Nandi S, Bhattacharjee S. CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapies. Cancer Cell Int. 2019;19:12. https://doi.org/10.1186/s12935-019-0726-0.

13. Bulaklak K, Gersbach CA. The once and future gene therapy. Nat Commun. 2020;11(1):5820. https://doi.org/10.1038/s41467-020-19505-2.

14. Boardman F. Human genome editing and the identity politics of genetic disability. J Community Genet. 2020;11(2):125–7. https://doi. org/10.1007/s12687-019-00437-4.

15. Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578(7794):229–36. https://doi.org/10.1038/s41586-020-1978-5.

16. Raper SE, Chirmule N, Lee FS, Wivel NA, Raag A, Gao GP, et al. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1–2):148–58. https://doi.org/10.1016/j.jmge.2003.08.016.

17. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulfraat N, Leboulch P, et al. LMO2-associated clonal T-cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415–9. https://doi.org/10.1126/science.1088547.

18. Amargioli N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6(2):e100029. https://doi.org/10.1371/journal.pmed.100029.

19. US Food and Drug Administration. Long term follow-up after administration of human gene therapy products. 2020. https://www.fda.gov/ media/113768/download. Accessed 30 June 2021.

20. European Medicines Agency. Guideline on follow-up of patients administered with gene therapy medicinal products. 2009. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-up-patients-administered-gene-therapy-medicinal-products_en.pdf. Accessed 30 June 2021.

21. Tse T, Williams RJ, Zarin DA. Reporting “basic results” in ClinicalTrials.gov. Ann Intern Med. 2016;165(6):421–30. https://doi.org/10.7326/ M15-2658.
24. Shepshelovich D, Goldvasser H, Wang L, AbdulRazak AR, Bedard PL. Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications. Invest New Drug. 2017;35(6):827–33. https://doi.org/10.1007/s10637-017-0510-8.

25. Tang E, Ravaud P, Riverso C, Perreau E, Dechartres A. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med. 2015;13:189. https://doi.org/10.1186/s12916-015-0430-4.

26. World Health Organization. Human Genome Editing (HGE) Registry. https://www.who.int/groups/expert-advisory-committee-on-developing-global-standards-for-governance-and-oversight-of-human-genome-editing/registry. Accessed 30 June 2021.

27. World Health Organization. WHO Trial Registration Data Set (Version 1.3.1). 2017. https://www.who.intclinical-trials-registry-platform/network-who-data-set. Accessed 30 June 2021.

28. Regalado A. China’s CRISPR babies: Read exclusive excerpts from the unseen original research. MIT Technology Review. 2019. https://www.mittechnologyreview.com/2019/12/03/131752/chinas-crispr-babies-read-exclusive-excerpts-he-jiankui-paper/. Accessed 30 June 2021.

29. Lander ES, Baylis F, Zhang F, Charpentier E, Berg P, Bourgain C, et al. Adopt a moratorium on heritable genome editing. Nature. 2019;567(7747):165–8. https://doi.org/10.1038/d41586-019-01078-5.

30. Wolinetz CD, Collins FS. NIH supports call for moratorium on clinical uses of germline gene editing. Nature. 2019;567(7747):175. https://doi.org/10.1038/d41586-019-00814-6.

31. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, et al. Clinical trial registration: looking back and moving ahead. Lancet. 2007;369(9577):1909–11. https://doi.org/10.1016/S0140-6736(07)68894-0.

32. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet. 2004;364(9438):911–2. https://doi.org/10.1016/S0140-6736(04)7037-4.

33. Final Rule: clinical trials registration and results information submission. Fed Regist 2016;81:64981e5157.

34. Wise J. Clinical trial reporting: compliance with US rules is poor and not improving, study finds. BMJ. 2020;368:m217. https://doi.org/10.1136/bmj.m217.

35. DeVito NJ, Goldacre B. Prevalence of clinical trial status discrepancies: a cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register. PLoS One. 2014;9(7):e101826. https://doi.org/10.1371/journal.pone.0101826. eCollection 2014.

36. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance of clinical trial registries with the World Health Organization’s International Study of the Adoption of ICMJE and Declaration of Helsinki reporting of trial number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and Declaration of Helsinki recommendations. BMJ. 2020;369:m982. https://doi.org/10.1136/bmj.m982.

37. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance of clinical trial registries with the World Health Organization’s International Study of the Adoption of ICMJE and Declaration of Helsinki reporting of trial number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and Declaration of Helsinki recommendations. BMJ. 2020;369:m982. https://doi.org/10.1136/bmj.m982.

38. World Health Organization Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. Human genome editing: recommendations. 2021. https://www.who.int/publications/i/item/9789240030381. Accessed 17 Feb 2022.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

MacKay M, Afshinmekoo E, Rub J, Hassan C, Khunte M, Baskaran N, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol. 2020;38(2):233–44. https://doi.org/10.1038/s41587-019-0329-2.

European Medicines Agency. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. 2020. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-aspects-medicinal-products-containing-genetically-modified-en.pdf. Accessed 30 June 2021.

Zhang J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11(1):132. https://doi.org/10.1186/s13045-018-0677-2.

Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9(19):1111. https://doi.org/10.1038/s41467-018-04252-2.

Hampton T. With first CRISPR trials, gene editing moves toward the clinic. JAMA. 2020;323(16):1537–9. https://doi.org/10.1001/jama.2020.3438.

Charlesworth CT, Deshpande PS, Dever DF, Caruana J, Lemgarten VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249–54. https://doi.org/10.1038/s41591-018-0326-x.

Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001;164(11):1612.

US Food and Drug Administration. CFR - Code of Federal Regulations Title 21, Volume S. Part 312 - Investigational New Drug Application. Subpart I - Expanded Access to Investigational Drugs for Treatment Use. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/cfCFRPart.cfm?CFRPart=312&showFR=1&subpartNode=21.501.1.1.9. Accessed 17 Feb 2022.

Borysowski J, Ehni HJ, Gorski A. Ethics review in compassionate use. BMC Med. 2017;15(1):136. https://doi.org/10.1186/s12916-017-0910-9.

Keams L, Chapman CR, Moch KL, Caplan AL, Watson T, McFadyen A, et al. Gene therapy companies have an ethical obligation to develop expanded access policies. Mol Ther. 2021;29(4):1367–9. https://doi.org/10.1038/s41598-021-00336-5.

Moja LP, Moschetti I, Nurbhai M, Compagnoi A, Liberati A, Grimshaw JM, et al. Compliance of clinical trial registries with the World Health Organization minimum data set: a survey. Trials. 2009;10:56. https://doi.org/10.1186/1745-6215-10-56.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomecentral.com/submissions